bempedoic acid
- Generic Name
- bempedoic acid
- Brand Names
- Nexletol, Nexlizet, Nilemdo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H36O5
- CAS Number
- 738606-46-7
- Unique Ingredient Identifier
- 1EJ6Z6Q368
- Background
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed...
- Indication
作为饮食和最大耐受性他汀类药物治疗的辅助药物，用于治疗患有杂合子家族性高胆固醇血症或需要额外降低LDL-C的动脉粥样硬化性心血管疾病的成人。
- Associated Conditions
- Atherosclerotic Cardiovascular Diseases, Heterozygous Familial Hypercholesterolemia (HeFH)
- Associated Therapies
- -
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06742853
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 2000
- Registration Number
- NCT06686615
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06450366
- Locations
- 🇮🇱
Yitzhak Shamir Medical Center. ( Site 0702), Beer Yaakov, Israel
🇮🇱Rambam Health Care Campus ( Site 0700), Haifa, Israel
🇮🇱Meir Medical Center. ( Site 0703), Kfar Saba, Israel
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Medanta, The Medicity, India
- Target Recruit Count
- 100
- Registration Number
- NCT06035874
- Locations
- 🇮🇳
Division Of Endocrinology , Medanta The Medicity Sec 38, Gurgaon, Haryana, India
A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05694260
- Locations
- 🇪🇸
Hospital Sant Joan de Deu, Barcelona, Spain
🇨🇦McMaster University Medical Center, Hamilton, Ontario, Canada
🇺🇸Continental Clinical Solutions, Towson, Maryland, United States
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Priscilla Hsue, MD
- Target Recruit Count
- 121
- Registration Number
- NCT05488431
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Bempedoic Acid Pregnancy Surveillance Program
- Conditions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05103254
- Locations
- 🇺🇸
Evidera, PPD business unit, Morrisville, North Carolina, United States
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT03337308
- Locations
- 🇺🇸
Foundation Cardiology, Nashua, New Hampshire, United States
🇺🇸PMG Research of Knoxville, Knoxville, Tennessee, United States
🇺🇸PMG Research of McFarland, Ames, Iowa, United States
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
- Conditions
- Interventions
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 1462
- Registration Number
- NCT03067441
- Locations
- 🇺🇸
Jedidiah Clinical Research, Tampa, Florida, United States
🇺🇸L-MARC Research Center, Louisville, Kentucky, United States
🇺🇸Sentral Clinical Research Services, Cincinnati, Ohio, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 269
- Registration Number
- NCT03001076
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.